About the study
Cure Glomerulonephropathy (CureGN) is a multi-center, international consortium of children and adults with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN) or IgA nephropathy/vasculitis (IgAN/IgAV). CureGN is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Since 2014, CureGN represents one of the largest observational cohort studies of adults and children with glomerular diseases and has continued to gain valuable information to better understand the cause of disease, response to therapy, and disease progression of glomerular diseases.
In addition to our research efforts, CureGN has strived for a patient-centered approach by connecting those with glomerular diseases to others and building a network of support for patients. By holding patient information sessions with CureGN study staff as well as peer support groups held by other patients, CureGN has created a valuable network of those with glomerular diseases from across the lifespan and continues to grow this network today.
Who We Are
The CureGN consortium is comprised of medical research professionals from around the world who study the following glomerular diseases: Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy (MN), and IgA Nephropathy (IgAN and IgAV).
The consortium is organized into the following groups:
Participating Clinical Centers
The four PCCs serve as clinical center hubs that coordinate the clinical sites in their CureGN duties. PCC hubs have primary responsibility for managing their associated clinical sites. They are responsible for participant enrollment, maintaining outstanding subject retention, and obtaining data and biospecimens of high quality. PCC administration directly oversees study coordinator training, and local regulatory and financial management.
Participants are recruited from each of the four Participating Clinical Center (PCC) networks: Columbia University, Pediatric Nephrology Research Consortium (PNRC), University of North Carolina (UNC), and University of Pennsylvania (PENN). Each PCC represents multiple clinical sites, with a current total of 65 sites, including 59 in the United States (US), four in Canada, one in Italy, and one in Poland.
Associate Professor of Medicine
Columbia University Medical Center
Marcus Professor of Pediatrics, Chief, Division of Pediatric Nephrology
Emory School of Medicine
Professor of Medicine
Director of Clinical and Translational Sciences Institute
University of Louisville
C. Robert Kidder Chair
Vice President, Clinical and Translational Research
Director, Center for Clinical and Translational Research
The Research Institute at Nationwide Children's Hospital
Professor of Pediatrics
The Ohio State University
Nan and Hugh Cullman Eminent Professor
Chairman, Department of Medicine
Co-Director, UNC Kidney Center
Chief, Renal-Electrolyte and Hypertension
C. Mahlon Kline Professor of Medicine
Professor of Pediatrics
Penn Medicine
Data Coordinating Center
The DCC provides organizational and administrative support for the study, supporting development and maintenance of study policies, managing consortium regulatory interactions, creating and maintaining the study database and data collection systems for CureGN, ongoing evaluation of data quality, performance monitoring of the PCCs, and statistical analyses of the data.
Chair, Department of Kidney Medicine, Medical Specialties Institute
Cleveland Clinic
Associate Professor of Nephrology
University of Michigan
Associate Professor of Biostatistics
Department of Preventative Medicine
Northwestern Medicine
Steering Committee
The Steering Committee is the study’s primary governing body, and includes PCC Principal Investigators (PIs), DCC PIs, a chairperson appointed by the NIDDK, and the NIDDK Project Scientist. The Steering Committee is responsible for study conduct in pursuit of consortium goals. Among other activities, it develops, approves, and updates the study protocol and policies; oversees study activities pertaining to participant recruitment and retention, biorepository and DPR functions, performance standards, access to patient data and specimens, ancillary studies, publications and presentations, and outside partnerships; and it resolves problems arising during study conduct.
Program Director, Hematology
Division of Kidney, Urologic and Hematologic Diseases (KUH)
NIH/NIDDK
Professor of Pediatrics, Children’s National Research Institute
Division of Kidney, Urologic, & Hematologic Diseases (KUH)
NIH/NIDDK
